fda warning about semaglutide Semaglutide: The Drug of Today and a Steppingstone to Tomorrow FDA Warns Against Using Compounded
Description
GLP-136510kg GLP-1FDAEU28 GLP-1 20212GLP-1
:max_bytes(150000):strip_icc()/HEALTH-DWL-frame-final-4-83ab587c91ea4eab9e89a0e86add8e41.jpg)
Progress takes time (often too much time), but it is happening
The work resulted in liraglutide, the first long-lasting GLP-1-based drug, approved by the US Food and Drug Administration in 2010 for type 2 diabetes
Large institutions and independent researchers alike need steady supply lines
The active ingredient in the incretin mimetic is dulaglutide, which shares 90% of the amino acid sequence with naturally occurring GLP-1
Important benchmark
